These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Fletcher EL; Phipps JA; Ward MM; Vessey KA; Wilkinson-Berka JL Prog Retin Eye Res; 2010 Jul; 29(4):284-311. PubMed ID: 20380890 [TBL] [Abstract][Full Text] [Related]
28. The angiogenic peptide vascular endothelial growth factor (VEGF) is expressed in chronic sacral pressure ulcers. Pufe T; Paulsen F; Petersen W; Mentlein R; Tsokos M J Pathol; 2003 May; 200(1):130-6. PubMed ID: 12692851 [TBL] [Abstract][Full Text] [Related]
29. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Ebrahimian TG; Tamarat R; Clergue M; Duriez M; Levy BI; Silvestre JS Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):65-70. PubMed ID: 15528473 [TBL] [Abstract][Full Text] [Related]
30. New approaches to the treatment of diabetic retinopathy. Porta M; Maldari P; Mazzaglia F Diabetes Obes Metab; 2011 Sep; 13(9):784-90. PubMed ID: 21535345 [TBL] [Abstract][Full Text] [Related]
31. [The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice]. Xie XW; Zhao P Zhonghua Yan Ke Za Zhi; 2004 Nov; 40(11):770-3. PubMed ID: 15634486 [TBL] [Abstract][Full Text] [Related]
32. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Funatsu H; Yamashita H; Ikeda T; Mimura T; Eguchi S; Hori S Ophthalmology; 2003 Sep; 110(9):1690-6. PubMed ID: 13129863 [TBL] [Abstract][Full Text] [Related]
33. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy? Williams B Miner Electrolyte Metab; 1998; 24(6):400-5. PubMed ID: 9930379 [TBL] [Abstract][Full Text] [Related]
34. Medical management of diabetic retinopathy: an overview. Malek M; Khamseh ME; Aghili R; Emami Z; Najafi L; Baradaran HR Arch Iran Med; 2012 Oct; 15(10):635-40. PubMed ID: 23020540 [TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Caldwell RW Diabetes Metab Res Rev; 2003; 19(6):442-55. PubMed ID: 14648803 [TBL] [Abstract][Full Text] [Related]
36. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Cooper ME Am J Hypertens; 2004 Nov; 17(11 Pt 2):16S-20S; quiz A2-4. PubMed ID: 15539106 [TBL] [Abstract][Full Text] [Related]
37. Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Yamagishi S; Matsui T; Nakamura K; Yoshida T; Shimizu K; Takegami Y; Shimizu T; Inoue H; Imaizumi T Microvasc Res; 2006 May; 71(3):222-6. PubMed ID: 16624340 [TBL] [Abstract][Full Text] [Related]
38. High levels of pigment epithelium-derived factor in the retina of a rat model of type 2 diabetes. Matsuoka M; Ogata N; Minamino K; Higuchi A; Matsumura M Exp Eye Res; 2006 Jan; 82(1):172-8. PubMed ID: 16054135 [TBL] [Abstract][Full Text] [Related]
39. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Moravski CJ; Kelly DJ; Cooper ME; Gilbert RE; Bertram JF; Shahinfar S; Skinner SL; Wilkinson-Berka JL Hypertension; 2000 Dec; 36(6):1099-104. PubMed ID: 11116132 [TBL] [Abstract][Full Text] [Related]
40. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Chaturvedi N; Fuller JH; Pokras F; Rottiers R; Papazoglou N; Aiello LP; Diabet Med; 2001 Apr; 18(4):288-94. PubMed ID: 11437859 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]